北京商报讯(记者丁宁)8月7日晚间，科源制药（301281）发布公告称，公司拟通过发行股份方式购买山 东宏济堂制药集团股份有限公司99.42%股权，同时募集配套资金，公司于7月10日收到深交所出具的 《关于山东科源制药股份有限公司发行股份购买资产并募集配套资金申请的审核问询函》(以下简称"审 核问询函")，要求公司收到审核问询函之日起30日内披露问询意见回复。 科源制药表示，鉴于审核问询函涉及的部分事项还需进一步落实，以上事项的完成所需工作时间较长， 预计无法在规定时间内完成回复工作。公司已向深交所申请，将延期至审核问询函回复届满之日起30日 内向深交所提交审核问询函回复文件等相关披露文件。延期期间，公司将与本次重组的交易各方及相关 中介机构尽快完成审核问询函的回复工作并及时履行信息披露义务。 ...

山东科源制药股份有限公司 证券代码：301281 证券简称：科源制药 公告编号：2025-052 关于延期回复《关于山东科源制药股份有限公司发行股份 购买资产并募集配套资金申请的审核问询函》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）拟通过发行股份方式购买 山东宏济堂制药集团股份有限公司99.42%股权，同时募集配套资金（以下简称"本 次交易"） 公司于2025年7月10日收到深圳证券交易所出具的《关于山东科源制药股份 有限公司发行股份购买资产并募集配套资金申请的审核问询函》（审核函〔2025〕 030007号）（以下简称"审核问询函"），要求公司收到审核问询函之日起30日 内披露问询意见回复。 根据审核问询函的要求，公司会同本次交易中介机构就审核问询函的反馈意 见进行逐项核查、落实和回复。鉴于审核问询函涉及的部分事项还需进一步落实， 以上事项的完成所需工作时间较长，预计无法在规定时间内完成回复工作。公司 已向深圳证券交易所申请，将延期至审核问询函回复届满之日起30日内向深圳证 券交易所提交审核问询函回复 ...

金融界消息 截至2025年8月5日收盘，科源制药（301281）报收于37.39元，下跌0.29%，换手率5.38%， 成交量3.70万手，成交金额1.39亿元。 资金流向方面，今日主力资金净流出1439.49万元，占比成交额10.38%。其中，超大单净流出253.91万 元、占成交额1.83%，大单净流出1185.58万元、占成交额8.55%，中单净流出流出494.55万元、占成交 额3.56%，小单净流入1934.04万元、占成交额13.94%。 通过天眼查大数据分析，山东科源制药股份有限公司共对外投资了5家企业，参与招投标项目108次，知 识产权方面有商标信息3条，专利信息65条，此外企业还拥有行政许可81个。 来源：金融界 天眼查商业履历信息显示，山东科源制药股份有限公司，成立于2004年，位于济南市，是一家以从事医 药制造业为主的企业。企业注册资本10829万人民币，实缴资本4550万人民币。公司法定代表人为高春 坡。 科源制药最新一期业绩显示，截至2025一季报，公司营业总收入1.11亿元、同比减少23.98%，归属净利 润2308.49万元，同比增长7.25%，扣非净利润1892.94万元，同比 ...

Group 1 - The stock price of Koyuan Pharmaceutical (301281) closed at 36.95 yuan on August 1, 2025, down 3.58% with a turnover rate of 9.41% and a trading volume of 64,800 hands, amounting to 244 million yuan [1] - The latest financial report for Koyuan Pharmaceutical shows total revenue of 111 million yuan for Q1 2025, a year-on-year decrease of 23.98%, while net profit attributable to shareholders was 23.08 million yuan, an increase of 7.25% [1] - The company has a current ratio of 6.622, a quick ratio of 5.235, and a debt-to-asset ratio of 12.23% [1] Group 2 - Koyuan Pharmaceutical has made investments in 5 companies and participated in 108 bidding projects [2] - The company holds 3 trademark registrations and 65 patents, along with 81 administrative licenses [2]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

证券日报网讯 7月29日晚间，科源制药发布公告称，公司于2025年7月28日召开职工代表大会进行第四 届监事会职工代表监事的补选，经与会职工代表投票，选举林岩先生担任公司第四届监事会职工代表监 事。 （编辑 姚尧） ...

二、补选公司职工代表监事的情况 鉴于李照文先生的辞职将导致公司监事会成员人数低于法定最低人数，且监 事会职工代表监事人数少于监事会成员的三分之一，为保证公司监事会的正常运 行，根据《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》及《公司章程》等有关规定，公司于2025年7月28日召开职 工代表大会进行第四届监事会职工代表监事的补选，经与会职工代表投票，选举 林岩先生（简历详见附件）担任公司第四届监事会职工代表监事，任期自本次职 证券代码：301281 证券简称：科源制药 公告编号：2025-050 山东科源制药股份有限公司 关于职工代表监事辞职暨补选的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司职工代表监事辞职的情况 山东科源制药股份有限公司（以下简称"公司"）监事会于近日收到公司职 工代表监事李照文先生的书面辞职报告。李照文先生因退休离任原因申请辞去公 司第四届监事会职工代表监事职务，辞职后李照文先生不在公司担任其他职务。 李照文先生原定任期至第四届监事会届满日（2027年9月29日）。 截至本公告披露日， ...

Core Insights - The company held a mid-year management meeting on July 19 to summarize achievements and shortcomings, analyze industry trends, and set strategic plans for the second half of the year [1][3] - The chairman and CEO, Gao Chunpo, emphasized the current pharmaceutical industry is undergoing a deep adjustment period with intensified competition and ongoing policy impacts, urging the company to find its market position amid these challenges [3][5] Group 1 - Each department head presented their work, achievements, innovations, challenges, and plans for the second half of 2025, showcasing the diligent efforts of the company [3] - Gao Chunpo highlighted the need for a long-term perspective to navigate through cyclical fluctuations and to create new opportunities amid changes [3][5] Group 2 - For the second half of the year, the chairman called for collaborative efforts across systems, focusing on market penetration, operational efficiency, and enhancing product competitiveness through technological improvements [5] - The meeting served as both a review of past work and a motivational rallying point for management to align on goals and drive high-quality development in the face of industry transformation [5]